SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

Discussion centers on the Trump-themed meme coins steep decline from past highs and losses for holders, alongside election-related political debate. Many traders call it a scam or expect further downside, while a smaller bullish group says they are accumulating or anticipating a rebound.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter results, fueled by growth in Dupixent and Eylea HD, drove a sharp share-price jump and a new 52-week high. Traders are broadly bullish on the breakout and upside-leaning options activity, while watching legacy Eylea declines and questioning whether the momentum can hold.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Speculation around a suspected pneumonic plague incident in Russia has renewed interest in EBS as a biodefense supplier, with traders pointing to heavier volume and possible short covering. The outbreaks link to a lab remains unconfirmed, and some traders doubt the news will sustain the move amid ongoing concerns about the companys debt and business outlook.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445402. The last known price of Zebec Network is 0.00197998 USD and is down -2.97 over the last 24 hours. It is currently trading on 133 active market(s) with $9,512,697.44 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Zebecs payments expansionespecially the MoneyGram-linked Stellar integrationis drawing attention, alongside discussion of Robinhood Chain support and European payroll deployments. Bulls view these developments as signs of growing real-world adoption, while skeptics argue that partnerships have yet to translate into sustained usage or token demand; separate Robinhood and BlackRock rumors remain unconfirmed.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne is selling off despite a strong Q3 earnings beat as traders focus on its comparatively restrained Q4 outlook, margin and product-mix concerns, and elevated valuation. Some view the AI-driven testing demand and results as reasons to buy the pullback, while others see the outlook as insufficient to justify the stocks valuation.

3M Co. is a technology company, which engages in manufacturing industrial, safety, and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Consumer, and Corporate. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment includes electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Consumer segment covers consumer healthcare, home care, home improvement, and stationery and office products, such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging, and consumer air quality solutions. The Corporate segment refers to special items and other corporate expenses. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle, and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

3M Co.

3M is drawing attention after a quarterly earnings beat and raised full-year outlook alongside an expanded Amazon partnership tied to data-center products. Bulls see a turnaround and AI-infrastructure growth opportunity, while skeptics argue the partnership is conditional and the recent rally may fade; traders are also watching heavy options activity.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is under pressure as traders point to falling lithium prices and a bearish tilt in options flow, with most of the cited premium in puts. Ahead of earnings, the community is split between expecting further downside if lithium pricing and guidance disappoint and viewing the decline as a potential buying opportunity.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Discussion centers on newly presented soquelitinib data in atopic dermatitis and the sharp selloff that followed, despite bullish traders calling the results encouraging. Skeptics question the early-stage evidence and safety follow-up, while others blame unmet expectations from the investor presentation and point to short interest as possible pressure.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Call-heavy options activity has drawn attention to Lennar as homebuilders rebound, with some traders viewing the flow and easing yields as supportive. Others remain cautious about mortgage-rate and affordability pressures weighing on housing demand.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,559,996,383.70523. The last known price of Dogecoin is 0.07552377 USD and is down -0.48 over the last 24 hours. It is currently trading on 1543 active market(s) with $337,365,256.17 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its weakness and range-bound trading below the 8-cent level, with repeated chart commentary describing bearish or consolidating conditions. Traders are split between buying the dip and expecting further losses, while some tie recent pressure to a broader crypto selloff and Binance-hack fears.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today

BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 14.31% on an annualized basis producing an average annual return of 28.04%. Currently, BeOne Medicines has a market capitalization ofread more...

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 2327...

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA (tislelizumab) plus...

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with...

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations...

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR  (ONC) Rating Upgrade to Strong Buy

BeOne Medicines Ltd. - Sponsored ADR  (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for October 15th

KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.

BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript

BeiGene (NASDAQ:ONC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financial data andread more...

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers

Equity

Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries. 

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

BeOne Medicines Ltd - ADR

Bearish Sentiment

<ul class="summary-bullets"><li>Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB inked deals with the Trump administration on Monday.&nbsp;</li><li>The nine companies pledged at least $19.6 billion in near-term U.S. factory spending.</li><li>U.S.-listed shares tied to the White House’s latest drug-pricing deals were quiet after the closing bell Monday, with no sharp move.</li></ul>President Donald Trump on Monday said nine mid-sized drugmakers have agreed to lower drug prices in the U.S., including Alcon (ALC), Astellas, BeOne Medicines (ONC), BridgeBio (BBIO), CSL, Kyowa Kirin, Sun Pharma, Teva (TEVA), and UCB.Under the deals, they would charge Americans no more than the lowest price paid in other rich countries, similar to big-pharma companies that inked similar deals with the Trump Administration last year. The medicines treat conditions such as cancer, Parkinson’s, hemophilia, eye disease, liver disease, and skin problems. The same rule would also apply to new drugs launched by these companies later.The nine companies pledged at least $19.6 billion in near-term U.S. factory spending. Some also said they will donate drug ingredients to a U.S. emergency reserve.U.S.-listed shares tied to the White House’s latest drug-pricing deals were quiet after the closing bell Monday, with no sharp move. Teva Pharmaceutical closed down 1.1%, then gained 2% in after-hours trading. BeOne Medicines finished down about 2%, and held that level after the close. BridgeBio was essentially flat in the regular session and ticked slightly higher after hours. Alcon shares were little changed.<h2 class="st-heading-2">Trump’s Pricing Push</h2>The fresh deals follow a push that began in 2025. Trump signed an order seeking “most-favored-nation” prices, then sent letters to 17 of the world’s largest drugmakers. He warned of tariffs on imports if they did not cut U.S. prices.Pfizer went first in September 2025. AstraZeneca and EMD Serono followed. In November, Eli Lilly and Novo Nordisk agreed to steep cuts on popular weight-loss and diabetes shots sold through TrumpRx.gov and at $50 a month for many Medicare patients.In December, nine more giants signed on in one day: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. Johnson &amp; Johnson and AbbVie followed in January. Regeneron was the last among the companies targeted by Trump to ink a most-favored-nation deal, after signing in April. Those earlier pacts mixed lower Medicaid prices, cash discounts on a government website, factory spending in the United States, and relief from drug tariffs.The White House said on Monday that earlier deals plus the fresh nine now cover 26 companies and 89% of the branded drug market. Every state Medicaid program would get those lower prices. Officials said that would save billions. The president’s economic team estimates all of the deals will save $600 billion over 10 years.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TEVA was bullish. Sentiment around BBIO and ONC, however, was neutral while ALC was bearish.Among those who inked deals with the administration on Monday, <a href="https://stocktwits.com/symbol/TEVA">TEVA</a> gained 16% year-to-date and <a href="https://stocktwits.com/symbol/ONC">ONC</a> 18%. ALC has fallen 9% year-to-date, while <a href="https://stocktwits.com/symbol/BBIO">BBIO</a> traded flat. 'Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-jumps-as-cybercabs-hit-texas-robotaxi-roster-ahead-of-launch-event/cZYz5JWRJsy">TSLA Stock Jumps as Cybercabs Hit Texas Robotaxi Roster Ahead Of Launch Event</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Brandon Wiley, Pharm D., pharmacist at Wiley Pharmacy in Lancaster, works at Wiley Pharmacy. Photo by Susan L. Angstadt 1/28/2015 (Photo By Susan L. Angstadt/MediaNews Group/Reading Eagle via Getty Images)

Alcon Inc. - Registered Shares

BridgeBio Pharma Inc

Teva- Pharmaceutical Industries Ltd. - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ONC #ESMO 
BeOne Medicines' ESMO Congress 2026 data highlights a strong competitive edge over standard treatments, showcasing high response rates, strong durability, and clean safety profiles across three key oncology programs.

Anne

$ONC is showcasing 12 abstracts and clinical data from its solid tumor portfolio at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (Oct 23-27). 
 
$ONC on the IBD List of *Institutional Buys* today ahead of the conference.  Morgan Stanley analyst raised his Price Target to $425.  Jefferies Price Target: $410.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ONC BeOne Medicines Ltd - ADR

Fundamentals

Latest ONC News